US Food and Drug Administration headquarters representing the reported withdrawal of Heidi Overton's nomination to lead the agency

FDA Nomination faces uncertainty following reports that President Donald Trump withdrew Heidi Overton's candidacy amid opposition in the US Senate

FDA Nomination: Trump Withdraws Heidi Overton’s Candidacy Amid Senate Opposition

White House reportedly considers Senator Roger Marshall as a replacement after concerns over vaccination policies, abortion medication and vaping complicate Overton’s confirmation.

WASHINGTON: US President Donald Trump has withdrawn Heidi Overton’s nomination to lead the Food and Drug Administration (FDA) after her candidacy failed to secure sufficient congressional support, according to three people familiar with the matter cited by Reuters.

The reported withdrawal came on Tuesday, just one day before a scheduled vote by the Senate Health, Education, Labor and Pensions (HELP) Committee.

Republicans held a narrow one-vote advantage on the committee, leaving Overton’s nomination vulnerable to opposition from even a single Republican member.

According to two people familiar with the discussions, the White House is considering Kansas Senator Roger Marshall, a former obstetrician who reportedly lost his recent reelection bid, as a potential replacement.

Trump nominated Overton in August following the resignation of former FDA Commissioner Marty Makary three months earlier.

Overton, a preventive medicine physician and deputy director of the White House Domestic Policy Council, was viewed as an ally of the administration’s America First policy agenda.

Her nomination came during a period of significant organisational challenges at the FDA, which the report said had lost more than 4,500 employees over the preceding year.

However, her confirmation prospects faced difficulties from the beginning, with disagreements over public health policies and regulatory decisions generating opposition among lawmakers and medical organisations.

Concerns about Overton’s support reportedly intensified following the November midterm elections, which the source described as resulting in major Republican losses and a shift in congressional control.

Several members of the Senate HELP Committee, including outgoing Chairman Bill Cassidy of Louisiana, Senator Susan Collins and Senator Roger Marshall, were reported to have lost their reelection campaigns.

Cassidy, a physician and Republican senator, had previously expressed reservations about Overton’s involvement in the administration’s proposed changes to childhood vaccination recommendations.

Overton appeared alongside Trump at an August event promoting an executive order that called for reducing the number of federally recommended childhood vaccinations.

The order also proposed separating the combined measles, mumps and rubella (MMR) vaccine into three individual injections.

According to people familiar with the discussions, Overton’s support for those measures raised concerns among medical organisations and career FDA officials, further complicating her confirmation prospects.

Despite the opposition, Senate Republicans reportedly continued efforts to secure sufficient votes ahead of Wednesday’s scheduled committee hearing.

Democratic lawmakers also criticised Overton’s position on reproductive healthcare, particularly her views concerning the abortion medication mifepristone.

Overton had opposed the Biden administration’s decision to ease certain dispensing restrictions on the medication.

The FDA is conducting a safety review of mifepristone, which the report said is expected to conclude by March 2027.

Meanwhile, some supporters of Health Secretary Robert F. Kennedy Jr.’s Make America Healthy Again movement reportedly questioned Overton’s connections with corporations they oppose.

Her position on electronic cigarettes also attracted criticism.

A nonpartisan advocacy organisation, Health in Office, launched a campaign opposing her nomination, distributing posters and signs that criticised her approach to vaping regulation.

At her September confirmation hearing, Overton defended the FDA’s reported May authorisation of fruit-flavoured vaping products, arguing that available evidence suggested such products could help some adult smokers stop using conventional cigarettes.

The issue added another source of controversy to a nomination already facing opposition over vaccination policies, reproductive healthcare and regulatory priorities.

According to the report, FDA Deputy Commissioner for Food Kyle Diamantas is currently serving as acting commissioner.

The withdrawal leaves the administration facing another leadership decision at the federal agency responsible for regulating medicines, vaccines, medical devices, food safety and tobacco products.

A replacement nominee would need to navigate the Senate confirmation process while addressing competing expectations from lawmakers, public health organisations and industry stakeholders.